| Tebas, Pablo |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery |
|
|
| Not yet recruiting | 2 | 99 | US | GLS-1200, Placebo, Sterile Saline | GeneOne Life Science, Inc. | Sinusitis Chronic | 12/23 | 09/24 | | |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 |
|
|
| Active, not recruiting | 1 | 15 | US | Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies | Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID) | HIV, HIV/AIDS, HIV-1 Infection | 12/21 | 10/22 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
| Active, not recruiting | 1 | 61 | US | dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device | Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals | Healthy Volunteers | 09/25 | 09/25 | | |
| Active, not recruiting | 1 | 12 | US | CD4 CAR+CCR5 ZFN T-cells | University of Pennsylvania | Hiv | 12/26 | 12/27 | | |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
| Campbell, Thomas B |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
NCT05414851: Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health |
|
|
| Completed | N/A | 45 | US | Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet | University of Rochester | Heart Disease, Ischemic, Hyperlipidemias, Hypertension | 04/24 | 04/24 | | |
| Gay, Cynthia |
NCT05261191: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy |
|
|
| Completed | 1 | 24 | US | MGD020, MGD014 | MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services | Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1 | 05/24 | 05/24 | | |
HVTN143, NCT05959707: Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants |
|
|
| Suspended | 1 | 77 | RoW | VRC01.23LS, PGT121.414.LS, PGDM1400LS | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 01/25 | 01/25 | | |
| Taiwo, Babafemi |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
|
|
| Active, not recruiting | 2 | 128 | US | VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20 | ViiV Healthcare | HIV Infections | 11/24 | 05/26 | | |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Completed | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 06/24 | 06/24 | | |
iCARE, NCT04950153: Intensive Combination Approach to Rollback the Epidemic in Nigerian Adolescents: UH3 Phase |
|
|
| Active, not recruiting | N/A | 558 | RoW | Peer navigation, SMS Text messaging, Social Media Engagement, Testing Peer Navigation | Northwestern University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Adolescent HIV Infection | 08/24 | 12/24 | | |
NCT06190613: Combination Intervention to Enhance Treatment Engagement and Viral Suppression Among Sexual and Gender Minority Youth in Nigeria |
|
|
| Recruiting | N/A | 100 | RoW | Combination Peer navigation and mHealth intervention | Northwestern University, National Institute of Mental Health (NIMH) | HIV | 08/26 | 08/26 | | |
| Gardner, Edward |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
| Recruiting | 2 | 1074 | US | Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo | Duke University | Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance | 07/25 | 07/25 | | |
NCT02028819: Compassionate Use of Ibalizumab for the Treatment of HIV Infection |
|
|
| No Longer Available | N/A | | US | Dolutegravir Sodium Monohydrate, TIVICAY, Ibalizumab, TMB-355 | University of Colorado, Denver | Human Immunodeficiency Virus (HIV) | 02/14 | 02/14 | | |
NCT05172024: Understanding the Long-term Impact of COVID-19 in Adults (RECOVER) |
|
|
| Active, not recruiting | N/A | 15178 | US | | NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI) | SARS-CoV2 Infection | 04/25 | 05/25 | | |
| Castillo-Mancilla, Jose R |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
| Active, not recruiting | N/A | 384 | US | | University of Colorado, Denver | Hiv | 05/25 | 05/25 | | |
NCT04065347: Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF) |
|
|
| Completed | N/A | 84 | US | Digital Pill, etectRx ID-Cap System | University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID) | HIV/AIDS, Adherence, Medication | 05/23 | 05/23 | | |
| Burke, Leah |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
| Recruiting | N/A | 300 | US | Acceptance and Commitment Therapy (ACT), Body weight circuit training, Empathetic social support, Control - list of resources | University of California, San Diego, Christie's Place, By His Stripes Wellness Center, Sister Love, APLA Health | HIV Infections, Substance Use, Trauma, Medication Adherence | 12/27 | 05/28 | | |
| Erlandson, Kristine |
| Completed | 3 | 602 | US | Pitavastatin, Placebos | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA) | HIV-1 Infection | 08/23 | 08/23 | | |
NCT04216589: Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) |
|
|
| Completed | 2 | 51 | US, RoW | Semaglutide | National Institute of Allergy and Infectious Diseases (NIAID), The University of Texas Health Science Center, Houston | HIV Infections, Non-Alcoholic Fatty Liver Disease | 03/23 | 09/23 | | |
| Active, not recruiting | 2 | 51 | US, RoW | Semaglutide | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1-infection, Adiposity, Insulin Resistance, Pre-diabetes, Hepatic Steatosis | 08/23 | 08/23 | | |
| Recruiting | 2 | 380 | US | IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care | Kanecia Obie Zimmerman | Long COVID, Long Covid19, Long Covid-19 | 12/25 | 03/26 | | |
| Recruiting | 2 | 1074 | US | Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo | Duke University | Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance | 07/25 | 07/25 | | |
| Not yet recruiting | 2 | 100 | US | Tesamorelin, Egrifta, TH9507, growth hormone-releasing hormone analogue, Placebo, Exercise | Massachusetts General Hospital, University of Colorado - Anschutz Medical Campus | HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging | 03/28 | 09/28 | | |
NCT04495348: Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance |
|
|
| Completed | N/A | 18 | US | Doravirine | University of Colorado, Denver, Gilead Sciences | HIV-1-infection, Weight Gain | 01/23 | 06/23 | | |
NCT05172024: Understanding the Long-term Impact of COVID-19 in Adults (RECOVER) |
|
|
| Active, not recruiting | N/A | 15178 | US | | NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI) | SARS-CoV2 Infection | 04/25 | 05/25 | | |
NCT04550676: High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV |
|
|
| Active, not recruiting | N/A | 118 | US | HIIT (intervention), CME (active control) | University of Colorado, Denver, Case Western Reserve University, University of Washington | Hiv, Fatigue, Mobility Limitation | 07/25 | 12/25 | | |
HEALTH-COG, NCT06013579: Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV |
|
|
| Recruiting | N/A | 110 | US | Phase 1 Gym Exercise HIIT, Phase 1 Gym Exercise CME, Phase 2 Home Exercise Coaching Text Messages, Phase 2 Home Exercise Control Text Messages | University of Alabama at Birmingham, University of Colorado, Denver, University of Washington, National Institute on Aging (NIA) | HIV Infections, Cognitive Impairment | 09/27 | 03/28 | | |
| Epperson, Kim |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV |
|
|
| Recruiting | 2 | 48 | US, RoW | Selgantolimod, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis B, HIV Infections | 11/26 | 05/27 | | |
| Recruiting | 2 | 90 | US, RoW | Estradiol | National Institute of Allergy and Infectious Diseases (NIAID) | HIV I Infection | 05/27 | 05/27 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/28 | 08/29 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
| Mahmoudi, Saniyyah |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents |
|
|
| Active, not recruiting | 1/2 | 168 | US, RoW | Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART) | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 02/23 | 06/25 | | |
NCT02140255: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission |
|
|
| Recruiting | 1/2 | 1120 | US, RoW | Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, DTG, VRC07-523LS | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH) | HIV Infection | 01/28 | 12/31 | | |
NCT04518228: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum |
|
|
| Recruiting | N/A | 325 | US, RoW | Bictegravir (BIC), Tenofovir alafenamide (TAF), Cabotegravir (CAB), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR) | National Institute of Allergy and Infectious Diseases (NIAID), International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme LLC | HIV Infections, Tuberculosis | 03/26 | 03/26 | | |
NCT05154513: Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV |
|
|
| Recruiting | N/A | 250 | US, RoW | Cohort 1 | International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH) | HIV Infection | 11/27 | 11/27 | | |
| Haakonsen, Nicola |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
| Recruiting | 2 | 90 | US, RoW | Estradiol | National Institute of Allergy and Infectious Diseases (NIAID) | HIV I Infection | 05/27 | 05/27 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
| Recruiting | N/A | 26 | US | Vertebral Body Augmentation, Manual Surgical Instruments | Lenoss Medical, MCRA, LLC | Vertebral Body Compression Fracture(s) | 08/22 | 12/22 | | |
| Fiorillo, Suzanne |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) |
|
|
| Active, not recruiting | 2 | 90 | US | CMV-MVA Triplex, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Cytomegalovirus Infections, HIV Infections, Vaccine | 11/24 | 10/25 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
| Doyle, Jamie |
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV |
|
|
| Recruiting | 2 | 48 | US, RoW | Selgantolimod, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis B, HIV Infections | 11/26 | 05/27 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) |
|
|
| Active, not recruiting | 2 | 90 | US | CMV-MVA Triplex, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Cytomegalovirus Infections, HIV Infections, Vaccine | 11/24 | 10/25 | | |
NCT06066957: Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients |
|
|
| Recruiting | 2 | 80 | US | Letermovir 480 MG [Prevymis] | University of Pennsylvania, Merck Sharp & Dohme LLC | Cytomegalovirus Infections, Transplant-Related Disorder | 08/26 | 08/26 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/28 | 08/29 | | |
| Wimpelberg, Avery A |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV |
|
|
| Recruiting | 2 | 48 | US, RoW | Selgantolimod, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis B, HIV Infections | 11/26 | 05/27 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
| Recruiting | 2 | 90 | US, RoW | Estradiol | National Institute of Allergy and Infectious Diseases (NIAID) | HIV I Infection | 05/27 | 05/27 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
| Pasternak, Julie |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV |
|
|
| Recruiting | 2 | 48 | US, RoW | Selgantolimod, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis B, HIV Infections | 11/26 | 05/27 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
| Recruiting | 2 | 90 | US, RoW | Estradiol | National Institute of Allergy and Infectious Diseases (NIAID) | HIV I Infection | 05/27 | 05/27 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
| Recruiting | N/A | 30 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1-infection | 07/29 | 09/29 | | |
